Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone and Flurbiprofen Axetil in NSCLC Surgery
NCT03172988Phase 4Terminated
- Sponsor
- Peking University First Hospital
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexamethasone and flurbiprofen axetil in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Peking University First Hospital. Primary endpoint: 3-year survival after surgery. Started Aug 2017; status: terminated.
02
Drugs
dexamethasoneflurbiprofen axetil
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03172988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172988.